Navigation Links
New Drug Shows Promise Against Huntington's Disease

MONDAY, Nov. 7 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.

Huntington's patients have an imbalance in the signaling chemical dopamine. The new drug stabilizes dopamine signaling in areas of the brain that control movement and coordination.

According to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily. The only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.

The results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.

The study included 437 Huntington's disease patients from eight European countries. The participants took either pridopidine (45 milligrams once daily or 45 mg twice daily) or a placebo for 26 weeks.

After six months of treatment, patients taking the higher dose of pridopidine showed improvements in motor function -- specifically in eye and hand movements, involuntary muscle contractions (dystonia), and gait and balance -- compared with patients taking the placebo.

More than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers. Side effects among patients taking the drug were similar to the placebo group.

"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits. Its lack of severe side-effects . . . suggests that pridopidine might be useful even for those patients who are treated at sites that are not centers of excellence for Huntington's disease," the researchers concluded.

One U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.

"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease," said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.

"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease. And, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last," he added.

Still, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.

"Unfortunately, Huntington's is a progressive disease and this drug is not a treatment of the disease itself but only improves some of its symptoms," he explained. "Nevertheless, it is a welcome addition because there is very little else yet available to treat the symptoms. The challenge for scientists and clinicians is to discover therapies that actually slows or halts the progression of the disease."

Another expert agreed that new treatment options for patients are sorely needed.

"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder," Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.

The study was funded by European pharmaceuticals company NeuroSearch A/S.

More information

We Move has more about Huntington's disease.

-- Robert Preidt

SOURCES: Alessandro Di Rocco, M.D., professor, department of neurology and chief, division of movement disorders, NYU Langone Medical Center, New York City; The Lancet Neurology, news release, Nov. 7, 2011

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene therapy shows promise as hemophilia treatment in animal studies
2. Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, UB study shows
3. New drug shows promise against multiple sclerosis
4. Preterm birth rate shows three year improvement in most states
5. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
6. Novel approach to treat proliferative vitreoretinopathy shows promise
7. New therapy shows promise for treating cardiovascular disease
8. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
9. New oncolytic virus shows improved effectiveness in preclinical testing
10. Clinical trial shows first evidence that anal cancer is preventable
11. Through-the-nipple breast cancer therapy shows promise in early tests
Post Your Comments:
Related Image:
New Drug Shows Promise Against Huntington's Disease
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare ... 7% over 2015-2016. Latin America has ... , (excluding Japan ), is second ... continues to face increased healthcare expenditure. In 2013-2014, total ... declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. In ...
Breaking Medicine Technology: